Updates in T Cell Engagers in Solid Tumors

T cell engagers are an established class of immunotherapies with proven survival benefit across multiple hematologic malignancies and certain solid tumors, including small cell lung cancer and uveal melanoma. With multiple phase III trials now underway across cancer types, these agents are rapidly reshaping the treatment landscape in oncology. The learning objectives of this session will be to review the mechanism of action, describe toxicities, and evaluate mechanisms of resistance of T cell engagers. The presentation will apply lessons learned from hematologic malignancies and from past and ongoing trials in solid tumors to inform the continued development of these agents across oncology.

Learning Objectives:

1. review the mechanisms of action of T cell engagers 

2. describe toxicities of T cell engagers 

3. evaluate mechanisms of resistance of T cell engagers